Live Breaking News & Updates on Early Phase Therapeutics Program

Stay updated with breaking news from Early phase therapeutics program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Afshin Dowlati , Athena Countouriotis , University Hospitals Seidman Cancer Center , International Conference On Molecular , Avenzo Therapeutics Inc , Early Phase Therapeutics Program , Allorion Therapeutics Inc , Therapeutics Announces Global License , Potentially Best In Class Clinical Stage , Investigational New Drug , Avenzo Therapeutics , Allorion Therapeutics , Greater China , Peter Ding , Case Western Reserve , Early Phase Therapeutics , Molecular Targets , Cancer Therapeutics , Therapeutics Contact ,

KB-0742 Exhibits Tolerable Safety and Activity in Relapsed/Refractory Solid Tumors

The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675). ....

United States , Miguel Villalona Calero , Therapeutics Research , Department Of Medical Oncology , International Conference On Molecular , Early Phase Therapeutics Program , Molecular Targets , Medical Oncology , Developmental Cancer Therapeutics Program , The Selective Cdk9 Inhibitor Kb 0742 , Heavily Pretreated Patients With Relapsed Refractory , Ranscriptionally Addicted Solid Tumors , Phase 1 Trial Nct04718675 , 2023 Aacr Nci Eortc International Conference On Molecular Targets And Cancer Therapeutics ,

Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid Tumors

Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma, and highlights the ongoing evaluation of the agent’s safety.
....

Miguel Villalona Calero , Department Of Medical Oncology Therapeutics Research , Developmental Cancer Therapeutics Program , Early Phase Therapeutics Program , Medical Oncology , Therapeutics Research , Onclive Tv , Kb 0742 ,

Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin Lymphoma

Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor. ....

United States , Miguel Villalona Calero , Kronos Bio , National Cancer Institute , American Association For Cancer Research , Developmental Cancer Therapeutics Program , Early Phase Therapeutics Program , Medical Oncology , Therapeutics Research , American Association , Cancer Research , Accessed May , Patients With Relapsed Or Refractory Solid Tumors , Non Hodgkin Lymphoma , Kb 0742 , City Of Hope ,

Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma. ....

United States , Miguel Villalona Calero , Early Phase Therapeutics Program , Developmental Cancer Therapeutics Program , Medical Oncology , Therapeutics Research , Kb 0742 , Patients With Relapsed Refractory Lymphoma Or Solid Tumors , Breast Cancer , Ovarian Cancer , Lung Cancer , Myc Expression , Non Hodgkin Lymphoma , City Of Hope ,